Effects of interferon beta-1b injection: A Synthesis of Findings from 30 Studies

  1. Home
  2. Effects of interferon beta-1b injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of interferon beta-1b injection: A Synthesis of Findings from 30 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of interferon beta-1b injection: A Synthesis of Findings from 30 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Interferon beta-1b injection is a treatment used for relapsing multiple sclerosis (MS). 27 shows that interferon beta-1b was the first disease-modifying therapy approved for the treatment of MS, and over 21 years of follow-up data demonstrate its efficacy and long-term safety profile. 19 suggests that for patients with a less-active relapsing form of MS, interferon beta-1b subcutaneous is similar in efficacy to interferon beta-1a intramuscular and subcutaneous. 22 assessed the influence of a personal digital assistant (PDA) with diary function on persistence and adherence to an interferon beta treatment regimen. 16 analyzed persistence and adherence in patients with MS receiving first-line treatment with subcutaneous glatiramer acetate, subcutaneous interferon β1a, intramuscular interferon β1a, and subcutaneous interferon β1b. 29 assessed compliance, the reasons for non-compliance, treatment satisfaction, and quality of life (QoL) of patients treated with first-line therapies. 20 shows that treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks. 26 evaluated the impact of a switch to fingolimod versus staying on each of the four individual injectable disease-modifying therapies (iDMTs) on patient- and physician-reported outcomes in relapsing multiple sclerosis.

Benefits and Risks

Benefit Summary

Interferon beta-1b injection is an effective treatment for relapsing multiple sclerosis, potentially reducing the frequency of relapses and slowing the progression of the disease. 27 shows that interferon beta-1b was the first disease-modifying therapy approved for the treatment of MS, and over 21 years of follow-up data demonstrate its efficacy and long-term safety profile. 19 suggests that for patients with a less-active relapsing form of MS, interferon beta-1b subcutaneous is similar in efficacy to interferon beta-1a intramuscular and subcutaneous. 20 shows that treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks.

Risk Summary

Interferon beta-1b injection has a risk of side effects, including injection site reactions, flu-like symptoms, depression, and elevated liver enzymes. 23 discusses the rates of common adverse events observed in 3 clinical trials of interferon β-1b. 17 shows that interferon beta-1b injection may, though rarely, cause morphea. 15 reports that interferon beta-1b injection may cause cutaneous necrotic lesions after years of administration.

Comparison between Studies

Commonalities

Many studies suggest that interferon beta-1b injection is effective in treating relapsing multiple sclerosis. They also indicate that interferon beta-1b injection carries some risk of side effects such as injection site reactions, flu-like symptoms, depression, and elevated liver enzymes. However, each study differs in terms of patient population, treatment methods, and outcomes assessed.

Differences

Studies evaluating the effectiveness and safety of interferon beta-1b injections vary in their patient populations, treatment methods, and outcomes assessed. For example, 19 focuses on patients with a less-active relapsing form of MS. 22 examines how electronic diaries impact the persistence and adherence to interferon beta treatment. 16 analyzes the persistence and adherence to interferon and glatiramer acetate treatment and identifies associated factors and reasons for discontinuation. These studies evaluate the effects of interferon beta-1b injection from different perspectives.

Consistency and Contradictions in Results

While many studies indicate that interferon beta-1b injection is effective in treating relapsing multiple sclerosis, the results of these studies vary in terms of patient population, treatment methods, and outcomes assessed. Therefore, it is challenging to interpret these results collectively. Some studies have also shown that interferon beta-1b injection carries certain risks of side effects, such as injection site reactions, flu-like symptoms, depression, and elevated liver enzymes. 17 shows that interferon beta-1b injection may, though rarely, cause morphea. 15 reports that interferon beta-1b injection may cause cutaneous necrotic lesions after years of administration. These findings suggest that further research into the safety of interferon beta-1b injection is needed.

Practical Implications

Interferon beta-1b injection is considered an effective treatment for relapsing multiple sclerosis, but the risk of side effects must also be taken into account. Individual patients' conditions and symptoms vary, so it is essential to consult with a doctor when choosing a treatment. If you have any questions or concerns regarding the risks of side effects or the treatment methods, consult your doctor.

Limitations of Current Research

Many studies have investigated the effectiveness and safety of interferon beta-1b injection. However, these studies differ in terms of patient population, treatment methods, and outcomes assessed. Therefore, interpreting their results collectively is challenging. Furthermore, additional research is needed to understand the long-term effects of interferon beta-1b injection.

Directions for Future Research

Studies are needed to assess the long-term effects of interferon beta-1b injection and to more thoroughly evaluate the risks of side effects. Additional research is also required to determine the optimal treatment approach for maximizing the effectiveness of interferon beta-1b injection while minimizing the risk of side effects.

Conclusion

Interferon beta-1b injection is considered an effective treatment for relapsing multiple sclerosis, but the risk of side effects must also be taken into account. When choosing a treatment, it is essential to consult with a doctor. If you have any questions or concerns regarding the risks of side effects or the treatment methods, consult your doctor.

Keywords
Benefit Keywords
Iron replenishment
1
Improved iron nutrition
Sustained iron levels
2
Improved iron absorption
3
Prevented ID
Prevented IDA
4
Effective treatment
5
Iron deficiency anemia reduction
6
Safe for pregnant women
7
Iron supplementation benefit
8
Iron deficiency treatment
9
Reduced anemia
Reduced birthweight
10
Decreased disease activity
MS treatment
11
MS treatment adherence
12
MERS mortality reduction
13
Reduced ICU admission
Shortened time to improvement
14
Complication prevention
Early diagnosis
15
MS Treatment
16
RMS treatment
18
Multiple sclerosis treatment
19
Improved convenience
Improved treatment satisfaction
20
Multiple sclerosis treatment
21
Persistence and adherence to interferon beta treatment regimen
22
Multiple sclerosis treatment
23
Relapse rate reduction
25
Multiple sclerosis treatment
26
MS treatment
27
Fingolimod satisfaction
28
High compliance
High satisfaction
29
Reduced relapses
Reduced risk of MS
30
Risk Keywords
Constipation
Side effects
1
Daily iron side effects
2
Gastrointestinal side effects
4
Gastrointestinal side effects
5
Abnormal behavior
6
Oxidative damage
8
Side effects
9
Unknown
10
Safety uncertainty
Significant disability
11
Adverse events
13
Interferon beta-1b injection site reaction
Severe skin reaction
15
Inflammatory dermatological side effects
Local reaction
Morphea
17
Not applicable
20
Flu-like symptoms
Injection site pain
21
Depression
Elevated liver transaminases
Flu-like symptoms
Injection site reactions
23
Septal panniculitis
24
Cardiac safety concerns
Hepatotoxicity
Teratogenicity
25
Insurance coverage issues
28
Discomfort
Flu-like symptoms
29
Asthenia
Chills
Depression
Headache
Hypoesthesia
Influenza-like syndrome
Injection site reactions
Insomnia
Myalgia
Myasthenia
Nausea
Paresthesia
30
Literature analysis of 30 papers
Positive Content
28
Neutral Content
1
Negative Content
1
Article Type
11
3
3
7
29
1.

Side effects of iron supplements in blood donors: superior tolerance of heme iron.

Author: FrykmanE, BystromM, JanssonU, EdbergA, HansenT

Iron replenishment
Constipation
Side effects

A study compared the side effects of two iron supplements: one with both heme and non-heme iron (Hemofer), and one with only non-heme iron (Erco-Fer). While both were equally effective in replenishing iron levels, Hemofer resulted in significantly fewer side effects, including constipation, compared to Erco-Fer and a placebo.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

2.

Long-term weekly iron supplementation improves and sustains nonpregnant women's iron status as well or better than currently recommended short-term daily supplementation.

Author: ViteriF E, AliF, TujagueJ

Improved iron nutrition
Sustained iron levels
Daily iron side effects

This study compared the efficacy of two iron supplementation schemes in improving iron nutrition in women. Weekly iron supplementation was found to be as effective as daily iron supplementation and better tolerated.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Iron absorption in breast-fed infants: effects of age, iron status, iron supplements, and complementary foods.

Author: DomellöfMagnus, LönnerdalBo, AbramsSteven A, HernellOlle

Improved iron absorption

This study investigated the effects of age, iron status, and iron intake on iron absorption in 25 healthy, term, breast-fed infants. Iron absorption from human milk remained low in iron-supplemented infants (16.9 +/- 9.3%) but was higher (P = 0.01) in unsupplemented infants (36.7 +/- 18.9%). Unexpectedly, iron absorption at 9 mo was not correlated with iron status but was significantly correlated with intake of dietary iron, including supplemental iron. Changes in the regulation of iron absorption between 6 and 9 mo enhance the infant's ability to adapt to a low-iron diet.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Efficacy and tolerability of low-dose iron supplements during pregnancy: a randomized controlled trial.

Author: MakridesMaria, CrowtherCaroline A, GibsonRobert A, GibsonRosalind S, SkeaffC Murray

Prevented ID
Prevented IDA
Gastrointestinal side effects

Supplementing pregnant women with 20 mg/d of iron from week 20 of gestation until delivery was effective in preventing iron deficiency anemia and iron deficiency without anemia. This low-dose iron supplementation did not result in significant gastrointestinal side effects.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Comparison of a combination ferrous fumarate product and a polysaccharide iron complex as oral treatments of iron deficiency anemia: a Taiwanese study.

Author: LiuTa-Chih, LinShen-Fung, ChangChao-Sung, YangWen-Chi, ChenTyen-Po

Effective treatment
Gastrointestinal side effects

This study compared the efficacy and tolerability of a ferrous iron supplement (Ferall) and a ferric iron polysaccharide complex (Niferex) in patients with iron deficiency anemia. The ferrous product was more effective, with slightly higher gastrointestinal side effects.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

6.

Effect of iron supplementation during pregnancy on the intelligence quotient and behavior of children at 4 y of age: long-term follow-up of a randomized controlled trial.

Author: ZhouShao J, GibsonRobert A, CrowtherCaroline A, BaghurstPeter, MakridesMaria

Iron deficiency anemia reduction
Abnormal behavior

Prenatal iron supplementation to reduce the incidence of iron deficiency anemia does not significantly impact the intelligence quotient (IQ) of offspring at 4 years of age. A randomized controlled trial of 430 pregnant women showed no significant difference in mean IQ between children of iron-supplemented mothers and those in the placebo group. However, the iron group had a higher percentage of children with abnormal behavior scores.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Effect of high-dose iron supplements on fractional zinc absorption and status in pregnant women.

Author: HarveyLinda J, DaintyJack R, HollandsWendy J, BullVictoria J, HoogewerffJurian A, FoxallRobert J, McAnenaLiadhan, StrainJ J, Fairweather-TaitSusan J

Safe for pregnant women

Iron supplementation during pregnancy did not adversely affect zinc metabolism in iron-replete pregnant women. Zinc absorption increased during late pregnancy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Impact of prophylactic iron supplementation in healthy pregnant women on maternal iron status and birth outcome.

Author: FalahiEbrahim, AkbariSoheila, EbrahimzadeFarzad, GargariBahram Pourghasem

Iron supplementation benefit
Oxidative damage

This study discusses the potential benefits and risks of iron supplementation in pregnant women.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

9.

Intermittent iron supplementation for improving nutrition and development in children under 12 years of age.

Author: De-RegilLuz Maria, JefferdsMaria Elena D, SylvetskyAllison C, DowswellTherese

Iron deficiency treatment
Side effects

Iron deficiency anemia is a common problem in children, affecting 600 million children worldwide. Daily iron supplementation has been used to improve iron status, but its effectiveness has been limited due to side effects, such as nausea, constipation or staining of the teeth. Intermittent iron supplementation may be a safer and more effective alternative to daily supplementation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

10.

Iron supplements in pregnant women with normal iron status: A systematic review and meta-analysis.

Author: HansenRebecka, SejerEmilie P F, HolmCharlotte, SchrollJeppe B

Reduced anemia
Reduced birthweight
Unknown

Daily oral iron supplementation in non-anemic iron replete pregnant women probably reduces the risk of iron deficiency anemia at term and low birthweight.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

11.

Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.

Author: TramacereIrene, VirgiliGianni, PerducaVittorio, LucenteforteErsilia, BenedettiMaria Donata, CapobussiMatteo, CastelliniGreta, FrauSerena, Gonzalez-LorenzoMarien, FeatherstoneRobin, FilippiniGraziella

Decreased disease activity
MS treatment
Safety uncertainty
Significant disability

Multiple sclerosis (MS) is a disease affecting the brain and spinal cord, primarily affecting young adults, with women being affected more often than men. While treatments for MS can slow the disease's progression, there's still uncertainty about their safety.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome.

Author: ArabiYaseen M, AsiriAyed Y, AssiriAbdullah M, BalkhyHanan H, Al BshabsheAli, Al JeraisyMajed, MandourahYasser, AzzamMohamed H A, Bin EshaqAbdulhadi M, Al JohaniSameera, Al HarbiShmeylan, JokhdarHani A A, DeebAhmad M, MemishZiad A, JoseJesna, GhazalSameeh, Al FarajSarah, Al MekhlafiGhaleb A, SherbeeniNisreen M, ElzeinFatehi E, Al-HameedFahad, Al SaediAsim, AlharbiNaif K, FowlerRobert A, HaydenFrederick G, Al-DawoodAbdulaziz, AbdelzaherMohamed, BajhmomWail, AlMutairiBadriah M, HusseinMohamed A, AlothmanAdel,

MERS mortality reduction
Adverse events

A combination of recombinant interferon beta-1b and lopinavir-ritonavir led to lower mortality than placebo among patients hospitalized with laboratory-confirmed Middle East respiratory syndrome (MERS). The effect was greatest when treatment was started within 7 days after symptom onset.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

14.

Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial.

Author: RahmaniHamid, Davoudi-MonfaredEffat, NourianAnahid, KhaliliHossein, HajizadehNooshin, JalalabadiNarjes Zarei, FazeliMohammad Reza, GhazaeianMonireh, YekaninejadMir Saeed

Reduced ICU admission
Shortened time to improvement

This study evaluated the efficacy and safety of interferon (IFN) β-1b in treating patients with severe COVID-19. The results indicate that IFN β-1b may shorten the time to clinical improvement, reduce the need for intensive care unit (ICU) admission and invasive ventilation, and improve overall outcomes. However, further research with larger sample sizes is needed to confirm these findings and to fully assess the survival benefit of IFN β-1b.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

15.

Cutaneous necrotic lesion: A wonderful delay adverse effect of interferon beta-1b injection for multiple sclerosis treatment.

Author: MozafariNikoo, SaffaeiAli, AlizadehMohammad, ShabaniMinoosh

Complication prevention
Early diagnosis
Interferon beta-1b injection site reaction
Severe skin reaction

A 55-year-old man experienced severe injection site reactions after 10 years of interferon beta-1b treatment for multiple sclerosis (MS). The reactions were diagnosed as skin and soft tissue necrosis, highlighting the potential for severe skin reactions to occur with long-term interferon beta-1b use.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

16.

Persistence and adherence to interferon and glatiramer acetate in patients with multiple sclerosis.

Author: Bartolomé-GarcíaEmma, Usarralde-PérezÁngela, Sanmartín-FenolleraPatricia, Pérez-EncinasMonserrat

MS Treatment

This study analyzed persistence and adherence to first-line treatments with subcutaneous glatiramer acetate, interferon β1a, and interferon β1b in patients with multiple sclerosis, identifying associated factors and reasons for discontinuation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

17.

Morphea secondary to interferon beta1b injection: a case and review of the literature.

Author: OzluEmin, KaradagAyse Serap, AkdenizNecmettin, UzuncakmakTugba Kevser, ZemheriEbru, OzkanliSeyma

Inflammatory dermatological side effects
Local reaction
Morphea

Interferon beta (IFNβ) is a common treatment for multiple sclerosis (MS) but can cause skin side effects. This case report describes a patient who developed morphea, a rare skin condition, after receiving IFNβ1b injections. This case highlights the importance of being aware of the potential for rare side effects, even with commonly used medications.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

18.

Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China.

Author: XuYan, MaoNingying, ChirikovViktor, DuFen, YehYu-Chen, LiuLi, LiuRuiqi, GaoXin

RMS treatment

This study estimated the cost-effectiveness of teriflunomide versus interferon beta-1b in patients with relapsing multiple sclerosis (RMS) from the perspective of the Chinese healthcare system.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

20.

Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks.

Author: HendinBarry, NaismithRobert T, WraySibyl E, HuangDeren, DongQunming, LivingstonTerrie, JonesDaniel L, WatsonCrystal, JhaveriMehul

Improved convenience
Improved treatment satisfaction
Not applicable

Switching patients with relapsing multiple sclerosis from other interferon (IFN) therapies to subcutaneous (SC) peginterferon beta-1a significantly improved treatment satisfaction, particularly in terms of convenience.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

21.

Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study.

Author: HoffmannFrank A, TrenovaAnastasiya, LlanezaMiguel A, FischerJohannes, LusGiacomo, von BredowDorothea, LaraNúria, LamElaine, Van HoefMarlies, BakshiRajesh

Multiple sclerosis treatment
Flu-like symptoms
Injection site pain

A new auto-injector, ExtaviPro™ 30G, improved patient satisfaction with interferon β-1b treatment for multiple sclerosis (MS). This may be related to reduced injection-site reactions and pain.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Language : English

22.

Adherence to Long-Term Interferon Beta-1b Injection Therapy in Patients with Multiple Sclerosis Using an Electronic Diary.

Author: ZettlUwe Klaus, Bauer-SteinhusenUlrike, GlaserThomas, CzekallaJörg, HechenbichlerKlaus, LimmrothVolker, HeckerMichael

Persistence and adherence to interferon beta treatment regimen

This study assessed the influence of a personal digital assistant (PDA) with diary function on persistence and adherence to interferon beta treatment for multiple sclerosis (MS). The PDA group showed better persistence and adherence compared to the paper diary group.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Language : English

24.

Severe septal panniculitis in a multiple sclerosis patient treated with interferon-beta.

Author: MazzonE, GuarneriC, GiacoppoS, RificiC, TchernevG, PolimeniG, WollinaU

Septal panniculitis

This report describes a case of severe septal panniculitis in an MS patient following subcutaneous administration of interferon beta-1b. The condition manifested as a painful, indurated, erythematous lesion at the injection site, highlighting a potential side effect of interferon beta-1b treatment.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
LetterA written message for communication and exchange of information between individuals.

Language : English

26.

Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.

Author: CalkwoodJonathan, CreeBruce, CraytonHeidi, KantorDaniel, SteingoBrian, BarbatoLuigi, HashmonayRon, AgashivalaNeetu, McCagueKevin, TenenbaumNadia, EdwardsKeith

Multiple sclerosis treatment

The EPOC study assessed physician- and patient-reported outcomes in individuals with relapsing multiple sclerosis switching from injectable disease-modifying therapy (iDMT) to fingolimod. Post hoc analyses indicated a favorable switch to fingolimod compared to staying on individual iDMTs.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

27.

Current perspectives on interferon Beta-1b for the treatment of multiple sclerosis.

Author: MarziniakMartin, MeuthSven

MS treatment

This review summarizes the clinical trial and follow-up data for interferon beta-1b, a disease-modifying therapy for multiple sclerosis (MS). The drug has been shown to be effective and safe over 21 years of follow-up data and is now one of seven first-line treatments for relapsing-remitting MS.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.